Generation Bio Co. Common Stock

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on targets in T cells that are undruggable or poorly drugged. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.